Atezolizumab Combo Effective in EGFR-Mutated Non-Small Cell Lung Cancer

The addition of atezolizumab to bevacizumab/carboplatin/paclitaxel (BCP) significantly prolongs overall survival in patients with non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to results of a final efficacy analysis presented this week at the European Medical Society for Oncology (ESMO) Virtual Congress 2020. "Atezolizumab inhibits programmed death-ligand 1 (PD-L1) to restore anti-cancer immunity; bevacizumab may enhance atezoli...
Continue reading

Brigatinib More Effective Than Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

A second interim analysis of the phase 3 ALTA-1L trial shows that brigatinib demonstrates superior results in patients with advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer (NSCLC) compared with crizotinib. Crizotinib is not the most effective therapy for patients with ALK-positive NSCLC, as disease progression occurs frequently in the central nervous system, possibly due to poor drug penetration. In previous phase 1/2 trials, brigatinib, a next-generation ALK inhibitor with ...
Continue reading

Ramucirumab/Erlotinib Approved: Metastatic Non-Small Cell Lung Cancer

The FDA has approved ramucirumab (Cyramza®, Eli Lilly and Company) in combination with erlotinib for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 substitution mutation. The approval was based on RELAY (NCT02411448), a phase 3 trial that enrolled 449 patients with untreated stage IV NSCLC. Eligible patients were at least 18 years old, had an Eastern Cooperative Oncology Group (ECOG) perfo...
Continue reading

Atezolizumab for PD-L1–High Non-Small Cell Lung Cancer: David Spigel, MD

Atezolizumab (Tecentriq®, Genentech, Inc.) was recently approved by the FDA for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high expression of programmed death ligand-1 (PD-L1). The approval was based on IMpower110, a phase 3 trial led by David Spigel, MD, Chief Scientific Officer and Director of the Lung Cancer Research Program at Sarah Cannon Research Institute in Nashville, Tennessee. In this interview with i3 Health, Dr. Spigel discusses the s...
Continue reading

FDA Approves Nivolumab/Ipilimumab/Platinum-Doublet Chemotherapy: NSCLC

Nivolumab (Opdivo®, Bristol Myers Squibb) plus ipilimumab (Yervoy®, Bristol Myers Squibb) in combination with 2 cycles of platinum-doublet chemotherapy has been FDA approved for treatment-naive patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Approval was based on the randomized, open-label trial CHECKMATE-9LA (NCT03215706). A total of 719 patients with met...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.